Laboratorio Reig Jofre SA
MAD:RJF

Watchlist Manager
Laboratorio Reig Jofre SA Logo
Laboratorio Reig Jofre SA
MAD:RJF
Watchlist
Price: 2.97 EUR 4.95%
Market Cap: 240.3m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one RJF stock under the Base Case scenario is 4.19 EUR. Compared to the current market price of 2.97 EUR, Laboratorio Reig Jofre SA is Undervalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RJF Relative Value
Base Case
4.19 EUR
Undervaluation 29%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
53
vs Industry
82
Median 3Y
0.6
Median 5Y
0.7
Industry
2.3
Forward
0.6
More Details
22.9
P/E
P/E
Price to Earnings
22.9
vs History
60
vs Industry
27
Median 3Y
20.6
Median 5Y
30
Industry
20.3
Forward
17.1
More Details
7.6
P/OCF
P/OCF
Price to OCF
7.6
vs History
92
vs Industry
31
Median 3Y
12.3
Median 5Y
13.8
Industry
15.1
More Details
17.9
P/FCFE
P/FCFE
Price to FCFE
17.9
vs History
52
vs Industry
4
Median 3Y
113.8
Median 5Y
20
Industry
22.3
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
44
vs Industry
61
Median 3Y
1
Median 5Y
1.1
Industry
1.9
More Details
0.7
EV/S
EV/S
Enterprise Value to Sales
0.7
vs History
58
vs Industry
83
Median 3Y
0.7
Median 5Y
0.9
Industry
2.4
Forward
0.6
More Details
1.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.3
vs History
58
vs Industry
83
Median 3Y
1.1
Median 5Y
1.4
Industry
4.8
More Details
6.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.6
vs History
65
vs Industry
43
Median 3Y
6.2
Median 5Y
8.2
Industry
12.2
Forward
5.9
More Details
16.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.8
vs History
71
vs Industry
30
Median 3Y
17.8
Median 5Y
25.1
Industry
15.2
Forward
14
More Details
8
EV/OCF
EV/OCF
Enterprise Value to OCF
8
vs History
92
vs Industry
28
Median 3Y
14.1
Median 5Y
15.5
Industry
13.7
More Details
23.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23.9
vs History
47
vs Industry
12
Median 3Y
22.2
Median 5Y
22.2
Industry
17.7
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
44
vs Industry
63
Median 3Y
0.8
Median 5Y
0.9
Industry
1.7
More Details

Multiples Across Competitors

RJF Competitors Multiples
Laboratorio Reig Jofre SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Laboratorio Reig Jofre SA
MAD:RJF
237.8m EUR 0.7 22.9 6.6 16.8
US
Eli Lilly and Co
NYSE:LLY
814.6B USD 18.1 76.9 44.7 49.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.1 17.6 11.6 13.2
CH
Roche Holding AG
SIX:ROG
207.8B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 18.9 11.4 14.7
UK
AstraZeneca PLC
LSE:AZN
162B GBP 4 30.7 126.2 192.8
US
Merck & Co Inc
NYSE:MRK
202.2B USD 3.2 11.8 8 9.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116B EUR 2.6 20.1 8.8 12.9
P/E Multiple
Earnings Growth PEG
ES
Laboratorio Reig Jofre SA
MAD:RJF
Average P/E: 26.8
22.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
76.9
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.6
18%
1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.7
36%
0.9
US
Merck & Co Inc
NYSE:MRK
11.8
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
20.1
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Laboratorio Reig Jofre SA
MAD:RJF
Average EV/EBITDA: 395.2
6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.7
31%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
8.8
6%
1.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Laboratorio Reig Jofre SA
MAD:RJF
Average EV/EBIT: 1 699.5
16.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
49.3
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
16%
0.8
CH
Roche Holding AG
SIX:ROG
11
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.8
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.5
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
12.9
14%
0.9

See Also

Summary
RJF intrinsic value, competitors valuation, and company profile.
DCF Valuation
RJF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RJF stock valuation using valuation multiples.
Wall Street Estimates
RJF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RJF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.